Recommendations on high-dose-rate rachytherapy for malignant tumors during COVID-19 epidemic
10.3760/cma.j.cn113030-20200619-00316
- VernacularTitle:新型冠状病毒病(COVID-19)疫情期间恶性肿瘤高剂量率近距离治疗推荐
- Author:
Ning ZHANG
1
;
Hongfu ZHAO
;
Guanghui CHENG
;
Zhipeng ZHAO
;
Zhuang MAO
Author Information
1. 吉林大学中日联谊医院放射治疗科，长春 130033
- From:
Chinese Journal of Radiation Oncology
2020;29(11):932-936
- CountryChina
- Language:Chinese
-
Abstract:
In China, COVID-19 epidemic is currently showing a sporadic state, and the task of epidemic prevention is still arduous. Brachytherapy (BT) plays a critical role in the treatment of cancer. For some cancer receiving radiotherapy, use of BT can not be replaced or excessively delayed. Nevertheless, the recommendations or guidelines regarding the application of BT during COVID-19 epidemic have been rarely reported. In this article, a few recommendations on the application of BT during COVID-19 epidemic were retrieved and the work experience of Department of Radiation Oncology, China-Japan Union Hospital of Jilin University in the early epidemic period was summarized, aiming to provide relevant reference for the use of high-dose-rate BT for malignant tumor patients during COVID-19 epidemic.
